Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial
Abstract Background Eptinezumab’s impact on self-reported work productivity in adults with migraine and 2‒4 prior preventive migraine treatment failures is not fully understood. Methodology Electronic diaries captured monthly migraine days (MMDs) reported by patients enrolled in the randomized, doub...
Saved in:
| Main Authors: | Piero Barbanti, Susanne F. Awad, Heather Rae-Espinoza, Stephane A. Regnier, Xin Ying Lee, Peter J. Goadsby |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-12-01
|
| Series: | Journal of Patient-Reported Outcomes |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41687-024-00813-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment
by: Junchen Chen, et al.
Published: (2025-07-01) -
Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study
by: Damiana Scuteri, et al.
Published: (2025-07-01) -
Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01) -
Developing a multidimensional scale for presenteeism: A study on measurement and implications
by: S. Mumlu-Karanfil, et al.
Published: (2024-11-01) -
Safety, efficacy, and compliance of moderate-to-high dose eptinezumab and erenumab in chronic migraine patients with medication-overuse headache: an updated systematic review and meta-analysis
by: Nhan Nguyen, et al.
Published: (2025-05-01)